

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

David M. Koelle et al.

Examiner:

Not yet assigned

Serial No.:

10/623,429

Group Art Unit:

1645

Filed:

July 18, 2003

Docket:

G&C 30967.11-US-U1

Title:

RAPID, EFFICIENT PURIFICATION OF HSV-SPECIFIC T-LYMPHOCYTES AND HSV

ANTIGENS IDENTIFIED VIA SAME

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 47, 2003.

Name: Karen S. Canady

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

We are transmitting herewith the attached:

Transmittal sheet, in duplicate, containing a Certificate of Mailing under 37 CFR 1.8.

☐ Information Disclosure Statement and Form PTO-1449.

☐ Cited Reference(s).

Return postcard.

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

Please charge all fees to Deposit Account No. 50-0494 of Gates & Cooper LLP. A duplicate of this paper is enclosed.

CUSTOMER NUMBER 22462

GATES & COOPER LLP

Howard Hughes Center 6701 Center Drive West, Suite 1050 Los Angeles, CA 90045 (310) 641-8797 Name: Karen S. Canady

Reg. No.: 39,927

KSC/sim

(PTO TRANSMITTAL - GENERAL)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

applicant:

David M. Koelle et al.

Examiner:

Not yet assigned

Serial No.:

10/623,429

Group Art Unit:

1645

Filed:

July 18, 2003

Docket:

G&C 30967.11-US-U1

Title:

RAPID, EFFICIENT PURIFICATION OF HSV-SPECIFIC T-LYMPHOCYTES

AND HSV ANTIGENS IDENTIFIED VIA SAME

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 17, 2003.

Name: Karen S. Canady

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(b))

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided (if required).

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art". Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please direct any response or inquiry to the below-signed attorney at (310) 641-8797.

Respectfully submitted,

GATES & COOPER LLP Attorneys for Applicant(s)

Howard Hughes Center 6701 Center Drive West, Suite 1050 Los Angeles, California 90045 (310) 641-8797

Date: November 17, 2003

KSC/sjm

Karen S. Canady

Reg. No.: 39,927

NOV

Form 1449*		Docket Number: G&C 30967.11-US-U	1 Application Number: 10/623,429	
INFORMATION DISCLOSURE STATEMENT		Applicants: David M. Koelle et al.		
IN AN APPLICATION		Filing Date: July 18, 2003	Group Art Unit:: 1645	

U.S. PATENT DOCUMENTS COPIES NOT REQUIRED FILING DATE IF DOCUMENT NO. DATE CLASS SUBCLASS NAME INITIAL APPROPRIATE 08/22/89 4,859,587 Roizman 04/23/02 6,375,952 D.M. Koelle 07/02/02 D.M. Koelle 6,413,518 **FOREIGN PATENTS COPY PROVIDED SUBCLASS** TRANSLATION DOCUMENT NO. DATE COUNTRY CLASS YES WO 98/20016 PCT (Seq. Tables excluded to 05/14/98 (pp 1-40 & 742-745) save paper) OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) **COPIES PROVIDED** E. De Plaen et al., "Cloning of Genes Coding for Antigens Recognized by Cytolytic T Lymphocytes," Immunology Methods Manual, 1997, 692-718 A. Dolan et al., "The Genome Sequence of Herpes Simplex Virus Type 2, Journal of Virology, 1998, 72(3):2010-2021 Koelle et al., "Recognition of Herpes Simplex Virus Type 2 Tegument Proteins by CD4 T Cells...." Jnl. of Virology, 1998, 72(9): 7476-7483 D.M. Koelle, "The Roles of T Lymphocytes in Host Responses to Herpes Simplex Virus," Herpes, 1995, 2:83-88 D.M. Koelle et al., "Clearance of HSV-2 from Recurrent Genital Lesions Correlates with Infiltration of HSV-Specific Cytotoxic T Lymphoctyes," The Journal of Clinical Investigation, 1998, 101(7):1500-1508 D.M. Koelle et al., "Preferrential Presentation of Herpes Simplex Virus T-Cell Antigen by HLA DOA1*0501/DQB1*0201 in Comparison to HLA DQA1*0201/DQB1*0201," Human Immunology, 1997, 53(2):195-205 D.M. Koelle et al., "Direct Recovery of Herpes Simplex Virus (HSV)-Specific T Lymphocyte Clones from Recurrent Genital HSV-2 Lesions," The Journal of Infectious Diseases, 1994, 169:956-61 D.M. Koelle et al., "Antigenic Specificities of Human CD+ T-Cell Clones Recovered from Recurrent Genital Herpes Simples Virus Type 2 Lesions," Journal of Virology, 1994, 68(5):2803-2810 W.W. Kwok et al., "Peptide Binding Affinity and pH Variation Establish Functional Thresholds for Activation of HLA-DQ-Restricted T Cell Recognition," Human Immunology, 1999, 60(7):619-626 Paoletti, "Applications of Pox Virus Vectors to Vaccination: An Update," Proceedings of the National Academy of Science USA, October 1996, 93:11349-11353 C.M. Posavad et al., "High Frequency of CD8⁺ Cytotoxic T-Lymphoctye Precursors Specific for Herpes Simplex Viruses in Persons with Genital Herpes," Journal of Virology, 1996, 70(11):8165-8168 S. Reichstetter et al., "MCH-Peptide Ligand Interactions Establish a Functional Threshold for Antigen-Specific T Cell Recognition," Human Immunology, 1999, 60(7):608-618

EXAMINER: DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

ed. Fields et al, Raven Press, 1991, New York, pp. 849-895.

B. Roizman et al., "Herpes Simplex Viruses and Their Replication", Fundamental Virology, 2nd Edition,

Sheet 2 of 2

Date Mailed: November 17, 2003

Form 1449*

INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION

Docket Number: G&C 30967.11-US-U1

Applicants: David M. Koelle et al.

Filing Date: July 18, 2003

Group Art Unit:: 1645

IPE	
10, 6	Stanberry, "Glycoprotein-D-Adjuvant Vaccine to Prevent Genital Herpes," N. Engl. J. Med., 2002,
	347(21):1652-1661
(NOV 1 8 ZULLS TELL)	M.A. Tigges et al., "Human CD8+ Herpes Simplex Virus-Specific Cytotoxic T-Lymphocyte Clones
\ NO! S	Recognize Diverse Virion Protein Antigens," Journal of Virology, 1992, 66(3):1622-1634
(F)	Williams et al., "Characterization of a Herpes Simplex Virus Type 2 Deoxyuridine" Virology, 1987,
THE THEORY AND THE	156:282-292
	Williams, "Deoxyuridine Triphosphate Nucleotidohydrolase Induced by Herpes Simplex Virus Type 1,"
	Jnl. of Biological Chemistry, 1984, 259(16): 10080-10084

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.